Valuation: Acrux Limited

Market Cap 6.16M 4.3M 3.77M 3.51M 3.23M 6.06M 411M 41.67M 16.31M 204M 16.13M 15.79M 703M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.23M 5.47M 5.09M 4.68M 8.78M 595M 60.42M 23.65M 295M 23.39M 22.89M 1.02B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 week-8.33%
Current month-8.33%
1 month-15.38%
6 months-26.67%
Current year-26.67%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.78
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.33%-38.89%-78.43% 3.95M
+0.42%+2.21%+16.10%+73.68% 49.38B
+1.45%+5.24%+59.84%+120.96% 36.35B
+1.02%+3.23%-7.19%+24.32% 11.87B
+0.76%-1.40%+11.62%+75.64% 11.53B
+0.38%+1.16%+31.33%+131.86% 8.99B
+3.41%+3.89%+50.47%-3.96% 7B
-0.51%-0.85%+11.77%+33.26% 6.76B
+1.62%+1.00%+2.97%+182.03% 6.46B
-1.32%-6.80%-33.10%-2.26% 5.49B
Average +0.77%-1.69%+10.49%+55.71% 14.38B
Weighted average by Cap. +0.88%+0.32%+24.83%+81.63%

Financials

2024 2025
Net sales 5.09M 3.55M 3.12M 2.9M 2.67M 5.01M 339M 34.44M 13.48M 168M 13.34M 13.05M 581M 1.19M 830K 729K 679K 624K 1.17M 79.32M 8.05M 3.15M 39.34M 3.12M 3.05M 136M
Net income -5.8M -4.05M -3.55M -3.31M -3.04M -5.7M -387M -39.24M -15.36M -192M -15.19M -14.86M -662M -5.94M -4.15M -3.64M -3.39M -3.12M -5.84M -396M -40.22M -15.74M -197M -15.57M -15.24M -679M
Net Debt 759K 530K 465K 433K 398K 746K 50.59M 5.13M 2.01M 25.09M 1.99M 1.95M 86.69M 2.77M 1.93M 1.7M 1.58M 1.45M 2.73M 185M 18.75M 7.34M 91.64M 7.26M 7.1M 317M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
29/07/26 A$0.0110 0.00% 1,429,995
28/07/26 A$0.0110 0.00% 2,638,948
27/07/26 A$0.0110 -8.33% 169,956
24/07/26 A$0.0120 0.00% 30,408
23/07/26 A$0.0120 0.00% 111,592

Annual profits - Rate of surprise